Business Infinity — Business Model Canvas

ASI Saga’s AI Boardroom: Dual‑Market Vision with Recursive & Exponential Network Effect

Customer Segments

  • Startups & scale‑ups: seed to Series‑C across all sectors
  • Enterprises & industrial conglomerates
  • Supply chain networks & consortia

Value Propositions

  • Persistent AI C‑suite agents trained on domain‑pioneer knowledge
  • Seamless orchestration over ERP, MES, CRM & SaaS
  • Inter‑boardroom protocols enabling 24/7 supply chain collaboration
  • Enterprise‑grade decision power for startups without enterprise bloat
  • Recursive learning loops — every node makes the network smarter

Channels

  • Startup accelerators & VC portfolios
  • ERP/MES/CRM vendor co‑sell
  • Industry events & thought leadership
  • Founder networks

Customer Relationships

  • Co‑created agent charters & governance workshops
  • Community of practice across boardrooms
  • Self‑serve onboarding for startups
  • High‑touch enterprise deployment & governance councils

Revenue Streams

  • Subscription per boardroom instance (role‑based tiers)
  • Usage‑based inter‑boardroom negotiation fees
  • Premium ERP/MES/CRM integrations
  • Domain tuning & charter design services

Key Resources

  • Domain‑specific LLM models & LoRA adapters
  • Integration middleware for ERP/MES/CRM/SaaS
  • Boardroom ontology, decision ledger & observability stack
  • Governance frameworks & escalation protocols
  • Partner ecosystem & domain corpora

Key Activities

  • Maintain & retrain domain‑tuned agents
  • Integrate enterprise & startup SaaS tools
  • Operate inter‑boardroom comms protocols
  • Facilitate recursive learning loops

Key Partners

  • ERP/MES/CRM vendors (SAP, D365, Salesforce, Odoo, Zoho)
  • System integrators & startup tech enablers
  • Incubators, accelerators, cloud credit programs
  • Industry consortia & regulatory bodies

Cost Structure

  • Model hosting & training
  • Integration & API maintenance
  • Security, compliance & audit
  • Customer success & community management
  • R&D for new agents & protocols